American Society of Hematology
1900 M Street, NW, Suite 200
Washington
D.C.
20036
United States
Tel: 202-776-0544
Fax: 202-776-0545
Website: http://www.hematology.org/
Email: ash@hematology.org
1237 articles about American Society of Hematology
-
New Recommendations Aim to Increase Capacity for Specialized Care for Adults Living with Sickle Cell Disease
8/12/2020
Paper is the first to define the requirements for establishment of dedicated adult sickle cell disease treatment centers
-
ASH Releases New Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults
8/6/2020
ASH published new guidelines to help older adults with acute myeloid leukemia and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care.
-
ASH Announces 2020 Honorific Award Recipients
6/23/2020
The American Society of Hematology congratulates this year's recipients of the Honorific Awards, the Society's most prestigious awards which recognize hematologists who have made significant contributions to the field.
-
ASH Releases New Clinical Practice Guidelines on Management of Pain in Sickle Cell Disease
6/19/2020
Pain guideline is the latest in Society's evidence-based series of clinical practice guidelines for sickle cell disease aiming to improve and personalize care for individuals with this complex condition
-
For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait
6/4/2020
Study suggests treatment delay does not increase risks and offers a window for selection of more personalized therapy
-
New MDS Subtype Proposed Based on Presence of Genetic Mutation
4/29/2020
International working group says the SF3B1 variant identifies a distinct disease entity, should inform WHO guidelines
-
Alleviating Confusion around Pain Management Recommendations
4/7/2020
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis--published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.
-
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
12/10/2019
CStone Pharmaceuticals updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology Annual Meeting.
-
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
12/10/2019
Innovent Biologics, Inc. announced that the latest clinical data of Fully-human BCMA CAR-T, a potential best-in-class cell therapy co-developed with IASO Biotherapeutics, has been presented in an oral session at the prestigious 61st Annual American Society of Hematology Meeting & Exposition convened in Orlando, FL, from 7 December 2019 to 10 December 2019.
-
Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting
12/10/2019
Stemline Therapeutics, Inc. presented data from ELZONRIS® Phase 1/2 clinical trials in myelofibrosis and multiple myeloma, at the 2019 ASH annual meeting.
-
BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting
12/10/2019
Trial Aims to Optimize Chemotherapy by Minimizing Dose Modifications Due to Chemotherapy-Induced Neutropenia or Bone Pain
-
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
-
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant
12/9/2019
Updated data from the Phase 3 ALCYONE study showed an overall survival benefit and continued improvement in progression-free survival after a median duration of follow-up of more than three years with DARZALEX®; results simultaneously published in The Lancet
-
Researchers at John Theurer Cancer Center, a Member of the Georgetown Lombardi Comprehensive Cancer Center Consortium, Participated in 46 Studies Presented at the 2019 American Society of Hematology's Annual Meeting & Exposition
12/9/2019
Experts at Hackensack Meridian Health John Theurer Cancer Center, a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, participated in 46 studies presented over the last week at the American Society of Hematology's 61st Annual Meeting & Exposition, held at the Orange County Convention Center in Orlando, FL from December 7-10.
-
Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
12/9/2019
Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB, presented data on the cost effectiveness of Doptelet® for the treatment of thrombocytopenia in patients with chronic liver diseases who are scheduled to undergo a procedure at the 61st Annual Meeting of the American Society of Hematology taking place in Orlando, 7-10 December.
-
FORMA Therapeutics Announces Clinical Data for Sickle Cell Disease Candidate FT-4202, Demonstrating Multi-modal Activity of PKR Activation Increases Oxygen Affinity and Decreases Sickle Hemoglobin Polymerization, at 61st Annual ASH Meeting
12/9/2019
Findings Indicate Safety, Tolerability and Proof of Mechanism in Healthy Volunteers, Support the Potential of FT-4202 to Beneficially Impact Hemoglobin Levels and Vaso-occlusive Crises
-
bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition
12/9/2019
CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18
-
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
12/9/2019
ArQule, Inc. announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase in patients with relapsed or refractory hematologic malignancies at the American Society of Hematology 2019 Annual Meeting & Exposition in Orlando, Florida.
-
TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent & in Triple Combination with Ublituximab & Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting & Exposition
12/9/2019
Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested
-
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
12/9/2019
CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies